SCHEMBL24427251

SCHEMBL24427251

Cc1nc(F)c(-c2ccc3c(N)noc3c2)[nH]1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 7/20 0.39
▸ F9 P00740 1/20 0.37
▸ CYP3A4 P08684 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ GFER P55789 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ JAK2 O60674 1/20 0.33
▸ LCK P06239 2/20 0.32
▸ CSF1R P07333 2/20 0.32
▸ IDO1 P14902 2/20 0.32
▸ MAP4K4 O95819 2/20 0.32
▸ CHEK1 O14757 1/20 0.32
▸ ABL1 P00519 1/20 0.32
▸ NTRK1 P04629 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24427626 0.84 MAPK14 (0.39) MAPK14F9KDM4ENPC1ALDH1A1
SCHEMBL24427339 0.82 MAPK14 (0.38) MAPK14CYP3A4PDGFRB
SCHEMBL24427512 0.79 MAPK14 (0.39) MAPK14F9CYP3A4KDM4ENPC1
SCHEMBL24427514 0.76 PDPK1 (0.52) JAK2KDRROCK1AURKBTGFBR1
SCHEMBL24427511 0.74 MAPK14 (0.34) MAPK14CYP3A4IDO1DYRK1A
SCHEMBL13525173 0.73 MAPK14 (0.45) MAPK14F9CYP3A4ALDH1A1JAK2
SCHEMBL24427252 0.73 F9 (0.41) MAPK14F9LCKCSF1RIDO1
SCHEMBL24427524 0.73 SCN9A (0.46) MAPK14KDRFLT3CDK8AURKB
SCHEMBL17832298 0.72 KDM4E (0.42) MAPK14CYP3A4KDM4ENPC1ALDH1A1
SCHEMBL24427249 0.70 F9 (0.41) MAPK14F9LCKCSF1RIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11518766-B2 Tricyclic compound, preparation method therefor and use thereof SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. (CN) 2022-12-06 — — US disclosed
EP-3998263-A1 TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) 2022-05-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11518766-B2 Tricyclic compound, preparation method therefor and use thereof TFPI, TFPI2, F11 MAPK14 282/4885F9 21/4885CYP3A4 220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback